NCT04684654View on ClinicalTrials.gov

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

PHASE1TerminatedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

July 25, 2023

Study Completion Date

July 25, 2023

Conditions
Healthy ParticipantsPrimary Sjögren's Syndrome
Interventions
BIOLOGICAL

BMS-986325

Specified dose on specified days

OTHER

Placebo for BMS-986325

Specified dose on specified days

Trial Locations (2)

10117

Local Institution - 0001, Berlin

91722

Medvin Clinical Research - Metyas, Covina

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04684654 - BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome | Biotech Hunter | Biotech Hunter